COMMUNIQUÉS West-GlobeNewswire

Bionano Reports Fourth Quarter and Full-Year 2025 Results and Provides Revenue Outlook for 2026
23/03/2026
Conference call today, March 23, 2026, at 4:30 PM ET SAN DIEGO, March 23, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the fourth quarter and full year ended [...]
Context Therapeutics Reports Full Year 2025 Operating and Financial Results
23/03/2026
Phase 1a interim data for ongoing trial of CTIM-76 (CLDN6 x CD3) expected in June 2026 Phase 1a interim data for ongoing trial of CT-95 (MSLN x CD3) expected in September 2026 Cash and cash equivalents of $66.0 million [...]
Inventiva annonce la publication et la présentation de ses résultats financiers annuels 2025
23/03/2026
Daix (France), New York ( États-Unis ), le 23 mars 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une thérapie orale [...]
Aardvark Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
23/03/2026
Voluntary pause of the Phase 3 HERO and OLE trials evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome, further guidance on the program expected in Q2 2026 ARD-201 obesity [...]
AFB Research Reveals Attitudes Toward and Reach of AI with Focus on Disability
23/03/2026
WASHINGTON, March 23, 2026 (GLOBE NEWSWIRE) -- The American Foundation for the Blind today released a new study on the experiences and perceptions of people with and without disabilities using AI. The report — The AI [...]
Outlook Therapeutics Announces Proposed Public Offering
23/03/2026
ISELIN, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, [...]
Sutro Biopharma Reports Full Year 2025 Financial Results and Business Highlights
23/03/2026
– Dosed three cohorts in Phase 1 trial of STRO-004, potential best-in-class Tissue Factor (TF) ADC; on track to report initial clinical data in mid-2026 – – Company announced first wholly owned dual-payload program [...]
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026
23/03/2026
Monday, March 30: Phase 1 data on TNX-4800 (long-acting anti-Borrelia OspA human monoclonal antibody) for the seasonal prevention of Lyme disease Wednesday, April 1: Animal and in vitro studies on TNX-801 (horsepox, [...]
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
23/03/2026
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on March 18, 2026 found no new safety signals; the analysis included 100% of [...]
Globus Medical Announces Board Departure
23/03/2026
AUDUBON, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced that John A. DeFord, PhD, a Director of Globus Medical Inc., notified the [...]
Avalyn Announces First Patient Dosed in AURA Phase 2 Clinical Trial Evaluating AP02, Inhaled Nintedanib, for the Treatment of Idiopathic Pulmonary Fibrosis
23/03/2026
AURA Phase 2 clinical trial designed to evaluate the safety and efficacy of AP02 compared to placebo in patients with idiopathic pulmonary fibrosis (IPF) BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Avalyn, a clinical- [...]
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
23/03/2026
BOSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, in November 2025 and on March 23, 2026, [...]
Inventiva Schedules the Publication and Presentation of its 2025 Full-Year Financial Results
23/03/2026
Daix (France), New York (United States), March 23, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
23/03/2026
Expect to submit an Investigational New Drug application for SZN-8141 to FDA in the second half of 2026 Scheduled to present retinal vascular research on SZN-8141 at the upcoming 2026 ARVO Annual Meeting Received notice [...]
OSE Immunotherapeutics invitée à présenter lors des prochaines conférences investisseurs
23/03/2026
Nantes, France, 23 mars 2026 – 18h00 CET – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et [...]
NMDP(SM) Advances Cell Therapy Research in Clinical Practice and Patient Outcomes at EBMT 2026
23/03/2026
Real-world data advances new insights into donor selection, benchmarks for patient infection prevention and comparative outcomes in a modern post-transplant cyclophosphamide (PTCy) era MINNEAPOLIS, March 23, 2026 (GLOBE [...]
OSE Immunotherapeutics to Present at Upcoming Investor Conferences
23/03/2026
Nantes, France, March 23, 2026 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a clinical-stage biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno- [...]
Stryker announces Annual Meeting of Shareholders
23/03/2026
Portage, Michigan, March 23, 2026 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2026 Annual Meeting of Shareholders is scheduled as follows: Wednesday, May 6, 2026 – 12:00 p.m. Eastern Time The Meeting will be [...]
MEDVi Quad Prescription Access Updated as Telehealth ED Treatment Demand Rises in 2026
23/03/2026
Los Angeles, March 23, 2026 (GLOBE NEWSWIRE) -- As demand for telehealth erectile dysfunction treatment access continues to grow in 2026, updated disclosures for MEDVi Quad , a prescription-only ED treatment, have been [...]

Pages